Get the Stockscreener App
130.28
1.79%
-2.38
Pre-market:
129.69
-0.59
-0.45%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $130.28, with a volume of 6.60M.
It is down -1.79% in the last 24 hours and down -0.16% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
See More
Previous Close:
$132.66
Open:
$132.29
24h Volume:
6.60M
Relative Volume:
1.16
Market Cap:
$225.95B
Revenue:
$41.95B
Net Income/Loss:
$13.40B
P/E Ratio:
17.03
EPS:
7.65
Net Cash Flow:
$6.35B
1W Performance:
-5.40%
1M Performance:
-0.16%
6M Performance:
+11.51%
1Y Performance:
+7.88%
1-Day Range:
$129.44
$132.61
1-Week Range:
$129.44
$139.15
52-Week Range:
$99.71
$140.84
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
130.28 | 225.95B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
96.42 | 142.29B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
363.84 | 138.83B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
91.51 | 117.34B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
68.51 | 40.28B | 5.72B | 4.17B | 259.90M | 6.97 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
Neurosurgery Market Size to Reach USD 6.8 Billion by 2034, Growing at 4.5% CAGR with Technological Advancements and Rising Focus on Personalized Medicine – Analysis by TMR - GlobeNewswire Inc.
Glucose Biosensor Market Booming with Technological Advancements | Industry Insights Abbott Laboratories, - EIN News
Here's Why We Think Abbott Laboratories (NYSE:ABT) Might Deserve Your Attention Today - Yahoo Finance
OTC Consumer Health Market Positioned for Accelerated Growth with Johnson&Johnson, Abbott Laboratories, - EIN News
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know - Nasdaq
Neurological Biomarkers: Global Market Review 2020-2024 and - GlobeNewswire
Abbott Laboratories (NYSE:ABT) Given New $150.00 Price Target at Bank of America - Defense World
Abbott Laboratories Options Trading: A Deep Dive into Market Sentiment - Benzinga
BofA Raises Price Target on Abbott Laboratories to $150 From $133 -March 10, 2025 at 10:06 am EDT - Marketscreener.com
Electroceutical Devices Market Projected To Witness Substantial Growth, 2025-2032: Medtronic plc, Abbott - EIN News
Abbott Laboratories Stock Analysis: Short-Term Gains vs. Long-Term ChallengesNews and Statistics - IndexBox, Inc.
3 Reasons to Avoid ABT and 1 Stock to Buy Instead - Yahoo Finance
Cancer Diagnostics Market Top PlayersGE Healthcare, Abbott - openPR
Shedd Aquarium receives $10 million pledge from Abbott - Philanthropy News Digest
ServiceNow, Abbott, Chipotle, Archer, T-Mobile Stock Shakeup! - TipRanks
Estimating The Fair Value Of Abbott Laboratories (NYSE:ABT) - Yahoo Finance
Abbott Labs sued for alleged ADA, human rights and whistleblower protection violations - Press Herald
Top Executive Cashes In on Abbott Laboratories Stock! - TipRanks
Abbott Laboratories EVP Lisa Earnhardt sells $12.2m in stock - Investing.com
Japan In-Vitro Diagnostics Market Forecast Report and - GlobeNewswire
Strong Earnings Lift Abbott Laboratories Shares - FX Empire
Citigroup Forecasts Strong Price Appreciation for Abbott Laboratories (NYSE:ABT) Stock - Defense World
Invest with Confidence: Intrinsic Value Unveiled of Abbott Labor - GuruFocus.com
Insider Sell: Andrea Wainer Sells Shares of Abbott Laboratories (ABT) - GuruFocus.com
Cadrenal and Abbott sign agreement for LVAD trial of tecarfarin - Medical Device Network
Padeiatricans’ summit sponsored by infant formula maker in violation of law - The Times of India
Abbott Laboratories (NYSE:ABT) Hits New 12-Month High on Analyst Upgrade - Defense World
Bioelectric Medicine Market Top Companies Study- Abbott - openPR
Drug Testing Market Is Booming Worldwide 2025-2032 | Abbott - openPR
Abbott Laboratories VP John McCoy Jr. sells $77,651 in stock By Investing.com - Investing.com South Africa
Abbott Laboratories SVP Eric Shroff sells $77,651 in stock - Investing.com
Abbott Laboratories retired EVP Andrea Wainer sells $131,123 in stock - Investing.com
Abbott Laboratories EVP Louis Morrone sells $153,506 in shares - Investing.com India
Abbott Laboratories EVP Mary Moreland sells shares worth $109,292 - Investing.com
Abbott Laboratories VP John McCoy Jr. sells $77,651 in stock - Investing.com
Healthcare Stocks Fall, Led Lower by SuppliersHealthcare Roundup -March 04, 2025 at 05:07 pm EST - Marketscreener.com
IRS Asks To Toss Abbott Labs' FOIA Action For Tax Records - Law360
Cognitive Enhancement Wearable Technology Patent Landscape - GlobeNewswire
Where Abbott Laboratories Stands With Analysts - Benzinga
Abbott Laboratories (NYSE:ABT) Partners With Cadrenal Therapeutics For TECH-LVAD Trial In Growing US$2B LVAD Market - Simply Wall St
Here's why Jim Cramer disagrees with latest Wall Street call on Abbott Labs - CNBC
He Fought Claims of Harm From Infant Formula. Now He Regulates It. - The New York Times
Patent Foramen Ovale Closure Devices Market is Booming - openPR
Cognitive Enhancement Wearable Technology Patent Landscape Report, 2017-2023 & 2024-2032 with Patent Profiles of Abbott Laboratories, IBM, Nestec, University of California, and Koninkl Philips Electronics - Yahoo Finance
Cadrenal partners with Abbott for heart device trial - Investing.com India
Can Cadrenal's Tecarfarin Revolutionize Treatment for HeartMate 3 LVAD Patients? - StockTitan
Drug Eluting Stents Market Is Booming So Rapidly: Abbott Laboratories, Boston Scientific Corporation - openPR
Is Abbott Laboratories' (NYSE:ABT) Stock's Recent Performance Being Led By Its Attractive Financial Prospects? - Yahoo Finance
Goldman Sachs Adjusts Price Target on Abbott Laboratories to $154 From $138, Keeps Buy Rating - Marketscreener.com
Gastritis Treatment Market Deep Research 2025-2032 | Abbott Laboratories, AstraZeneca PLC - openPR
A secretary turned $180 into $7.2 million by holding her employer's stock for 75 years - AOL
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
0.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):